Schütz W, Steurer G, Tuisl E, Plass H
Biochem J. 1984 May 15;220(1):207-12. doi: 10.1042/bj2200207.
In cellular systems provided with activatory (Ra-site) receptors for adenosine, such as rat cerebral microvessels and rat liver plasma membranes, the adenosine-receptor antagonist 8-phenyltheophylline (10 microM) significantly decreased adenylate cyclase activity if ATP was the substrate and only if GTP was present. With dATP as substrate, adenylate cyclase activities in both preparations remained unaffected by 8-phenyltheophylline. In rat cerebral-cortical membranes, with inhibitory (Ri-site) receptors for adenosine, 8-phenyltheophylline significantly enhanced adenylate cyclase activity only in the presence of GTP and if ATP was the substrate. In rat cardiac ventricular membranes, which are devoid of any adenylate cyclase-coupled adenosine receptor, the methylxanthine had no GTP-dependent effect, irrespective of the substrate used. All assay systems contained sufficiently high amounts of adenosine deaminase (2.5 units/ml), since no endogenous adenosine, formed from ATP, was found chromatographically. In order to demonstrate a direct influence of phosphorylated adenosine derivatives on adenylate cyclase activity, we investigated AMP in a dATP assay system. AMP was verified chromatographically to remain reasonably stable under the adenylate cyclase assay conditions. In the microvessels, AMP increased enzyme activity in the range 0.03-1.0 mM, an effect competitively antagonized by 8-phenyltheophylline. In the cortical membranes, 0.1 mM-AMP inhibited adenylate cyclase, which was partially reversed by the methylxanthine. The presence of GTP was again necessary for all observations. In the ventricular membranes, AMP had no effect. Since the efficacy of adenosine-receptor agonists and, probably, that of other hormones on adenylate cyclase activity can be more efficiently measured with dATP as the enzyme substrate, this nucleotide seems preferable for adenylate cyclase measurements in systems susceptible to modulation by adenosine.
在具有腺苷激活型(Ra位点)受体的细胞系统中,如大鼠脑微血管和大鼠肝细胞膜,若以ATP为底物且仅在存在GTP的情况下,腺苷受体拮抗剂8-苯基茶碱(10微摩尔)可显著降低腺苷酸环化酶活性。以dATP为底物时,两种制剂中的腺苷酸环化酶活性均不受8-苯基茶碱的影响。在具有腺苷抑制型(Ri位点)受体的大鼠大脑皮层膜中,8-苯基茶碱仅在存在GTP且以ATP为底物时,才会显著增强腺苷酸环化酶活性。在没有任何与腺苷酸环化酶偶联的腺苷受体的大鼠心室膜中,无论使用何种底物,甲基黄嘌呤均无GTP依赖性作用。所有测定系统均含有足够高量的腺苷脱氨酶(2.5单位/毫升),因为通过色谱法未发现由ATP形成的内源性腺苷。为了证明磷酸化腺苷衍生物对腺苷酸环化酶活性的直接影响,我们在dATP测定系统中研究了AMP。通过色谱法验证,AMP在腺苷酸环化酶测定条件下保持相当稳定。在微血管中,AMP在0.03 - 1.0毫摩尔范围内增加酶活性,该作用被8-苯基茶碱竞争性拮抗。在皮层膜中,0.1毫摩尔的AMP抑制腺苷酸环化酶,甲基黄嘌呤可部分逆转该抑制作用。所有观察结果均再次表明GTP的存在是必要的。在心室膜中,AMP无作用。由于以dATP作为酶底物可以更有效地测定腺苷受体激动剂以及可能其他激素对腺苷酸环化酶活性的作用,因此对于易受腺苷调节的系统,这种核苷酸似乎更适合用于腺苷酸环化酶的测定。